For example, in BrafV600E melanoma preclinical models, the progressive loss of CD8+ T cell response is partially restored through the over-activation of PPARα-driven FAO in an oxygen- and glucose-deprived TME, using PPARα agonist, like fenofibrate [117]. This evidence concerns the gene CD8A and melanoma.